Association of hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD) variants and colorectal cancer risk

Carcinogenesis

Volumn 32, Issue 2, 2011, Pages 190-196

  Frank, Bernd ^a   Hoeft, Birgit ^a   Hoffmeister, Michael ^a   Linseisen, Jakob ^a,b   Breitling, Lutz P ^a   Chang Claude, Jenny ^a   Brenner, Hermann ^a   Nieters, Alexandra ^a,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE;

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79251560031     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq231     Document Type: Article

References (41)

1. Parkin,D.M. et al. (2005) Global cancer statistics, 2002. CA Cancer J. Clin., 55, 74-108.
2. Ferlay,J. et al. (2004) GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARCPress, Lyon, France.
3. Pisani,P. et al. (2002) Estimates of the worldwide prevalence of cancer for 25 cancers in the adult population. Int. J. Cancer, 97, 72-81.
4. Potter,J.D. (1999) Colorectal cancer: molecules and populations. J. Natl Cancer Inst., 91, 916-932.
5. Lichtenstein,P. et al. (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med., 343, 78-85.
6. Verkasalo,P.K. et al. (1999) Genetic predisposition, environment and cancer incidence: a nationwide twin study in Finland, 1976-1995. Int. J. Cancer, 83, 743-749.
7. Ahlbom,A. et al. (1997) Cancer in twins: genetic and nongenetic familial risk factors. J. Natl Cancer Inst., 89, 287-293.
8. Wang,D. et al. (2008) Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett., 267, 197-203.
9. Wang,M.T. et al. (2007) Cyclooxygenases, prostanoids and tumor progression. Cancer Metastasis Rev., 26, 525-534.
10. Jones,R. et al. (2003) Arachidonic acid and colorectal carcinogenesis. Mol. Cell. Biochem., 253, 141-149.
11. Ensor,C.M. et al. (1995) 15-Hydroxyprostaglandin dehydrogenase. J. Lipid Mediat. Cell Signal., 12, 313-319.
12. Mann,J.R. et al. (2006) Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. Cancer Res., 66, 6649-6656.
13. Tai,H.H. et al. (2002) Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat., 68-69, 483-493.
14. Tseng-Rogenski,S. et al. (2010) Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression. Am. J. Pathol., 176, 1462-1468.
15. Chi,X. et al. (2009) 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells. Arch. Biochem. Biophys., 487, 139-145.
16. Thiel,A. et al. (2009) 15-hydroxyprostaglandin dehydrogenase is downregulated in gastric cancer. Clin. Cancer Res., 15, 4572-4580.
17. Yan,M. et al. (2009) 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc. Natl Acad. Sci. USA, 106, 9409-9413.
18. Huang,G. et al. (2008) 15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer. Cancer Res., 68, 5040-5048.
19. Liu,Z. et al. (2008) Expression of 15-PGDH is downregulated by COX-2 in gastric cancer. Carcinogenesis, 29, 1219-1227.
20. Tai,H.H. et al. (2007) 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer. Prostaglandins Other Lipid Mediat., 83, 203-208.
21. Wolf,I. et al. (2006) 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res., 66, 7818-7823.
22. Backlund,M.G. et al. (2005) 15-Hydroxyprostaglandin dehydrogenase is downregulated in colorectal cancer. J. Biol. Chem., 280, 3217-3223.
23. Myung,S.J. et al. (2006) 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc. Natl Acad. Sci. USA, 103, 12098-12102.
24. Cha,Y.I. et al. (2007) NSAIDs and cancer prevention: targets downstream of COX-2. Annu. Rev. Med., 58, 239-252.
25. Hoeft,B. et al. (2010) Polymorphisms in fatty acid metabolism-related genes are associated with colorectal cancer risk. Carcinogenesis, 31, 466-472.
26. Frank,B. et al. (2010) Colorectal cancer and polymorphisms in DNA repair genes WRN, RMI1, and BLM. Carcinogenesis, 31, 442-445.
27. Brenner,H. et al. (2006) Does a negative screening colonoscopy ever need to be repeated? Gut, 55, 1145-1150.
28. Lilla,C. et al. (2006) Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption. Cancer Epidemiol. Biomarkers Prev., 15, 99-107.
29. Fakhrai-Rad,H. et al. (2002) Pyrosequencing: an accurate detection platform for single nucleotide polymorphisms. Hum. Mutat., 19, 479-485.
30. Breslow,N.E. et al. (1980) Statistical methods in cancer research. Volume I-the analysis of case-control studies. IARC Sci. Publ., 32, 5-338.
31. Stephens,M. et al. (2005) Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am. J. Hum. Genet., 76, 449-462.
32. Stephens,M. et al. (2001) A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet., 68, 978-989.
33. Dupont,W.D. et al. (1998) Power and sample size calculations for studies involving linear regression. Control. Clin. Trials, 19, 589-601.
34. Riboli,E. et al. (2002) European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr., 5, 1113-1124.
35. Seifert,W. et al. (2009) HPGD mutations cause cranioosteoarthropathy but not autosomal dominant digital clubbing. Eur. J. Hum. Genet., 17, 1570-1576.
36. Poole,E.M. et al. (2010) Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma. Cancer Epidemiol. Biomarkers Prev., 19, 547-557.
37. Greene,C.S. et al. (2009) Failure to replicate a genetic association may provide important clues about genetic architecture. PLoS One, 4, e5639.
38. Lasky-Su,J. et al. (2008) On the replication of genetic associations: timing can be everything!. Am. J. Hum. Genet., 82, 849-858.
39. Kittles,R.A. et al. (2002) CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum. Genet., 110, 553-560.
40. Knowler,W.C. et al. (1988) Gm3;5,13,14 and type 2 diabetes mellitus: an association in American Indians with genetic admixture. Am. J. Hum. Genet., 43, 520-526.
41. Hirschhorn,J.N. et al. (2002) A comprehensive review of genetic association studies. Genet. Med., 4, 45-61.